vTv Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	36.84	-	1.02	-	2.02	4.01
Revenue Growth	216600.00%	-	-	-	-49.61%	-37.56%
Cost of Revenue	28.68	17.86	11.55	13.6	12.36	12.62
Gross Profit	8.16	-17.86	-10.53	-13.6	-10.34	-8.62
Selling, General & Admin	17.41	14.95	13.65	11.91	12.2	11.44
Operating Expenses	17.41	14.95	13.65	11.91	12.2	11.44
Operating Income	-9.25	-32.81	-24.18	-25.5	-22.54	-20.06
Interest Expense	-0.01	-0.01	-	-0.01	-0.02	-0.01
Interest & Investment Income	2.91	1.87	1.57	0.47	0.35	0
Other Non Operating Income (Expenses)	-0.06	-0.14	0.01	0.57	0.92	1.61
EBT Excluding Unusual Items	-6.4	-31.08	-22.61	-24.47	-21.29	-18.46
Merger & Restructuring Charges	-	-	-	-	-	-1.6
Gain (Loss) on Sale of Investments	-	-	-	-1.18	-3.59	2.45
Other Unusual Items	-	-	-	-0.31	-	-
Pretax Income	-6.4	-31.08	-22.61	-25.97	-24.87	-17.62
Income Tax Expense	-	-	0.1	-	0.2	0.12
Earnings From Continuing Operations	-6.4	-31.08	-22.71	-25.97	-25.07	-17.73
Minority Interest in Earnings	1.65	4.11	4.24	5.72	5.91	4.74
Net Income	-4.76	-26.97	-18.46	-20.25	-19.16	-12.99
Net Income to Common	-4.76	-26.97	-18.46	-20.25	-19.16	-12.99
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	11	8	6	2	2	2
Shares Outstanding (Diluted)	11	8	6	2	2	2
Shares Change	74.02%	45.96%	176.79%	8.60%	22.58%	32.90%
EPS (Basic)	-0.42	-3.20	-3.20	-9.71	-9.98	-8.29
EPS (Diluted)	-0.42	-3.20	-3.20	-9.71	-9.98	-8.29
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-16.76	-25.26	-25.31	-19.08	-16.04	-19.31
Free Cash Flow Per Share	-1.48	-3.00	-4.38	-9.15	-8.36	-12.33
Gross Margin	22.16%	-	-	-	-	-215.21%
Operating Margin	-25.11%	-	-2377.58%	-	-1116.95%	-500.92%
Profit Margin	-12.91%	-	-1815.34%	-	-949.65%	-324.27%
Free Cash Flow Margin	-45.50%	-	-2488.40%	-	-795.00%	-482.10%
EBITDA	-9.25	-32.79	-24.09	-25.41	-22.45	-19.97
EBITDA Margin	-25.10%	-	-	-	-	-
D&A For EBITDA	0.01	0.02	0.09	0.09	0.09	0.09
EBIT	-9.25	-32.81	-24.18	-25.5	-22.54	-20.06
EBIT Margin	-25.11%	-	-	-	-	-

SEC Filings: 10-K · 10-Q